{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:34Z","timestamp":1792004374384,"version":"4.4.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shionogi & Co., Ltd., Osaka, Japan"},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023961","name":"CIBERINFEC","doi-asserted-by":"publisher","award":["CB21\/13\/00084"],"award-info":[{"award-number":["CB21\/13\/00084"]}],"id":[{"id":"10.13039\/501100023961","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III, Spain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The PERSEUS study was a retrospective analysis of cefiderocol use under the compassionate use and early access programmes in Spain for the treatment of MDR Gram-negative infections. We present the microbiological evaluation of 57 isolates collected from this study, along with their correlation to clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cefiderocol susceptibility testing was performed using standard broth microdilution (BMD) in iron-depleted media, commercial BMD panels (UMIC\u00ae, ComASP\u00ae), gradient MIC strips, and disk diffusion. Results were interpreted according to EUCAST 2024 criteria. WGS was used to characterize \u03b2-lactamase genes and mutations in genes implicated in cefiderocol resistance. Patients\u2019 clinical charts were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most isolates were identified as Pseudomonas aeruginosa (72%). Cefiderocol demonstrated an overall susceptibility rate of 86%, outperforming most comparators except colistin. Commercial BMD devices demonstrated high concordance with the reference method, supporting their potential value for routine use. Molecular analysis revealed a high prevalence of class B metallo-\u03b2-lactamases, as well as mutations in iron transport genes, among resistant isolates. Notably, clinical cure was achieved even in patients infected with cefiderocol-resistant isolates treated with cefiderocol monotherapy, suggesting that some putative resistance mechanisms affect the MIC, without necessarily leading to clinical failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Positive clinical outcomes in patients infected by cefiderocol-resistant isolates by EUCAST breakpoints highlight the need for standardized susceptibility testing, as well as deeper genotype-phenotype correlation studies. Cefiderocol remains a promising option for treating MDR Gram-negative infections, especially those caused by P. aeruginosa. Its adoption in clinical practice should be supported by validated testing methods and ongoing surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag164","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:58:06Z","timestamp":1777377486000},"source":"Crossref","is-referenced-by-count":1,"title":["Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-3173","authenticated-orcid":false,"given":"Rafael","family":"Cant\u00f3n","sequence":"first","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS) , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Castillo","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS) , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2857-2572","authenticated-orcid":false,"given":"Marta","family":"Hern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS) , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel \u00c0ngel","family":"Sastre-Femen\u00eda","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases, Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-2005","authenticated-orcid":false,"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases, Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ruiz-Garbajosa","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS) , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Garc\u00eda Labrador","sequence":"additional","affiliation":[{"name":"Shionogi S.L.U. Medical Affairs, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[{"name":"Medical Affairs, Shionogi B.V. , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases, Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026052523033922000_dkag164-B1","author":"WHO"},{"key":"2026052523033922000_dkag164-B2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2026052523033922000_dkag164-B3","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026052523033922000_dkag164-B4","author":"Committee for Medicinal Products for Human Use (CHMP)"},{"key":"2026052523033922000_dkag164-B5","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052523033922000_dkag164-B6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ijantimicag.2018.11.005","article-title":"Stability of cefiderocol against clinically significant broad-spectrum oxacillinases","volume":"52","author":"Poirel","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2026052523033922000_dkag164-B7","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1093\/jac\/dky317","article-title":"Stability and low induction propensity of cefiderocol against chromosomal AmpC \u03b2-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae","volume":"73","author":"Ito","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026052523033922000_dkag164-B9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052523033922000_dkag164-B10","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01474-24","article-title":"In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including \u03b2-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals","volume":"12","author":"Kimbrough","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2026052523033922000_dkag164-B11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/jac\/dkad200","article-title":"In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)","volume":"78","author":"Takemura","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B12","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/jac\/dkae126","article-title":"In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain","volume":"79","author":"Maruri-Aransolo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B13","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1093\/jac\/dkac241","article-title":"Activity of cefiderocol, imipenem\/relebactam, cefepime\/taniborbactam and cefepime\/zidebactam against ceftolozane\/tazobactam and ceftazidime\/avibactam-resistant Pseudomonas aeruginosa","volume":"77","author":"Lasarte-Monterrubio","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B14","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/jac\/dkad172","article-title":"In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa","volume":"78","author":"Gomis-Font","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","article-title":"Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"30","author":"Karakonstantis","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026052523033922000_dkag164-B16","doi-asserted-by":"publisher","first-page":"447.e1","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026052523033922000_dkag164-B17","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/jac\/dkac221","article-title":"Evolution of \u03b2-lactamase-mediated cefiderocol resistance","volume":"77","author":"Fr\u00f6hlich","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B18","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04936-22","article-title":"In vitro activity of cefiderocol compared to other antimicrobials against a collection of metallo-beta-lactamase-producing Gram-negative bacilli from southern Spain","volume":"11","author":"Delgado-Valverde","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026052523033922000_dkag164-B19","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03836-23","article-title":"In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2026052523033922000_dkag164-B20","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/jac\/dkad134","article-title":"Comparison of ComASP\u00ae and UMIC\u00ae methods with the reference method for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales","volume":"78","author":"Emeraud","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/antibiotics12030604","article-title":"Disc diffusion and ComASP\u00ae cefiderocol microdilution panel to overcome the challenge of cefiderocol susceptibility testing in clinical laboratory routine","volume":"12","author":"Bianco","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026052523033922000_dkag164-B22","author":"EUCAST"},{"key":"2026052523033922000_dkag164-B23","author":"EUCAST"},{"key":"2026052523033922000_dkag164-B24","author":"EUCAST"},{"key":"2026052523033922000_dkag164-B25","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.3390\/diagnostics14202318","article-title":"Issues with cefiderocol testing: comparing commercial methods to broth microdilution in iron-depleted medium\u2014analyses of the performances, ATU, and trailing effect according to EUCAST initial and revised interpretation criteria","volume":"14","author":"Stracquadanio","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026052523033922000_dkag164-B26","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/jac\/dkad149","article-title":"Performance evaluation of the UMIC\u00ae cefiderocol to determine MIC in Gram-negative bacteria","volume":"78","author":"Dortet","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B27","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026052523033922000_dkag164-B28","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s10096-025-05109-5","article-title":"Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026052523033922000_dkag164-B29","author":"International Organization for Standarization (ISO)"},{"key":"2026052523033922000_dkag164-B30","author":"EUCAST"},{"key":"2026052523033922000_dkag164-B31","author":"CLSI"},{"key":"2026052523033922000_dkag164-B32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/cmb.2012.0021","article-title":"SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing","volume":"19","author":"Bankevich","year":"2012","journal-title":"J Comput Biol"},{"key":"2026052523033922000_dkag164-B33","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1093\/jac\/dks261","article-title":"Identification of acquired antimicrobial resistance genes","volume":"67","author":"Zankari","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100736","article-title":"Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis","volume":"34","author":"Sastre-Femenia","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026052523033922000_dkag164-B35","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/antibiotics12050910","article-title":"Stenotrophomonas maltophilia infections: a systematic review and meta-analysis of comparative efficacy of available treatments, with critical assessment of novel therapeutic options","volume":"12","author":"Maraolo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026052523033922000_dkag164-B36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jac\/dkad396","article-title":"In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity","volume":"79","author":"Gill","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026052523033922000_dkag164-B37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","article-title":"A review on colistin nephrotoxicity","volume":"71","author":"Ordooei Javan","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2026052523033922000_dkag164-B38","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab026","article-title":"Colistin nephrotoxicity: meta-analysis of randomized controlled trials","volume":"8","author":"Eljaaly","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026052523033922000_dkag164-B39","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae169","article-title":"Real-world performance of susceptibility testing for cefiderocol: insights from a prospective multicentre study on Gram-negative bacteria","volume":"6","author":"Irigoyen-Von-Sierakowski","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026052523033922000_dkag164-B40","author":"International Organization for Standarization (ISO)"},{"key":"2026052523033922000_dkag164-B41","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag164\/68387766\/dkag164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag164\/68387766\/dkag164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:03:52Z","timestamp":1779764632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag164\/8693058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag164","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"dkag164"}}